Objectives: High-frequency repetitive transcranial magnetic stimulation (HF-rTMS) has proven antidepressant effects, but the optimal frequency of sessions remains unclear.
A large number of patients with major depressive disorder (MDD) do not respond to 2 or more antidepressant medication treatments. [1] [2] [3] Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive method to stimulate the brain. [4] [5] [6] Several studies, involving patients with MDD, were conducted with the use of high-frequency rTMS (HF-rTMS). [7] [8] [9] The HF-rTMS has antidepressant effects in sham-controlled trials 10, 11 and naturalistic studies, [12] [13] [14] [15] with efficacy supported in several recent systematic reviews and meta-analyses. [16] [17] [18] [19] [20] [21] However, there are concerns regarding the quality of some studies 5 and the definition of optimum treatment indications and regimen. 22, 23 One important unresolved issue is the number of times per day that HF-rTMS should be delivered. 24 Loo et al, 25 in a 2-week randomized controlled trial (RCT), found that twice a day HF-rTMS is safe and better than placebo but did not compare twice a day rTMS with once a day. We are not aware of any study directly comparing twice a day versus once a day rTMS for treatment of treatment-resistant major depression (TRD). We present here results of an RCT to assess the antidepressant efficacy of 2 HF-rTMS sessions per day versus 1 session per day versus sham stimulation once or twice a day in patients with TRD.
MATERIALS AND METHODS

Sample Recruitment
The study was approved by the Eginition University Hospital Research Ethics Committee and was consistent with the Declaration of Helsinki. The trial protocol with reference no. 0527821514 can be accessed at http://www.eginitio.gr/Erevna/. The study is registered at http://controlled-trials.com/ISRCTN71929667. Patients were recruited from the outpatient service of Eginition Hospital, Athens, Greece between July 2006 and December 2011. Eligible subjects had to be aged 18 to 59 years, right handed, meet DSM-IV-TR criteria 26 for current nonpsychotic MDD, be naive to TMS, and without history of seizures, head injury with loss of consciousness, brain surgery, presence of metallic implants, dementia or other Axis I diagnosis, substance dependence or abuse within the previous 6 months, or pregnancy; diagnoses were confirmed using the Mini-International Neuropsychiatric Interview 27 and the Structured Clinical Interview for DSM-IV Axis I Disorders. 28 Patients had to be at least stage 2 treatment resistant (failure of at least 2 adequate trials of 2 different major classes of antidepressant) according to criteria by Thase and Rush. 29 Patients referred for treatment were screened for eligibility. Of the 177 patients screened, 105 were found eligible. All subjects were provided with full written information about the nature and purpose of the study, and 98 gave written informed consent to participate (Table 1) .
If clinically appropriate, subjects were encouraged to discontinue medication before study entry. If this was not possible, subjects were kept on a minimum antidepressant regimen, to not risk a recurrence of severe depressive symptoms (venlafaxine, 75-112.5 mg/d; mirtazapine, 30-45 mg/d; and citalopram, 20-30 mg/d); if taking benzodiazepines, a dosage no greater than the equivalent of 1 mg clonazepam per day was permitted. The medication regimen was kept stable for at least 4 weeks before study entry and throughout the study period.
Design
The study was a parallel-group, randomized, sham-controlled trial with 4 treatment groups: the once-daily active stimulation group (A1), the twice-daily active stimulation group (A2), the once-daily sham stimulation group (S1), and the twice-daily sham stimulation group (S2) ( Table 1) . To ensure allocation concealment, after baseline assessment by trained physician raters, patients were randomly assigned to receive a course of active or sham rTMS once or twice a day by an independent researcher using a passwordprotected computer database containing the randomization list.
Treaters were residents in psychiatry who were blind to the study protocol and naive to rTMS; they were told this was a study comparing 2 methods of active rTMS. Treaters were not allowed to deliver rTMS outside the study and were advised not to discuss the study protocol with patients and raters.
Patients had 15 (once a day) or 30 (twice a day) treatment sessions on consecutive weekdays (starting Monday) for 3 weeks. All the patients would come in the morning at approximately 8:00 AM for the first treatment session (both once and twice a day) and in the afternoon at approximately 5:00 PM if they were scheduled for a second treatment session (only twice a day). Patients and raters were blind to allocated treatment; only physicians responsible for the study protocol (C.T., C.P., and P.S.) knew the treatment being delivered. To check blinding, patients were asked to guess which treatment had been received ("active TMS," "sham TMS," or "can't guess") at the beginning of visit 2 and after visit 15 and raters after visit 15. The period of clinical assessment was extended 2 more weeks beyond the completion of rTMS sessions because we have an indication that rTMS sometimes produces a late effect for some of the patients.
The TMS Procedure
The HF-rTMS sessions took place in the TMS Unit, Eginition Hospital, Athens, Greece. At screening, experienced TMS researchers identified and marked on a swim cap (separate for each subject) the vertex, the scalp location for optimal 30 If the fiducial intended to be over PFC was actually over the premotor cortex, it was moved 1 cm anterior (this occurred in 34.7% of patients). At the beginning of each treatment session, motor threshold (MT) was determined by delivering single TMS pulses to the motor cortex for the right first dorsal interosseous muscle with continuous EMG monitoring. The MT was defined as the percentage output of the stimulator that induced at least a 50-μV motor evoked potential in 5 of 10 single stimulations. After baseline, MTwas determined once more at the beginning of the eighth rTMS session.
Treaters used a Magstim ultrarapid stimulator (Magstim Company Ltd, Whitland, United Kingdom), with a figure-8 magnetic coil applied over PFC. Each session of HF-rTMS treatment consisted of approximately 40 trains of 20 Hz at 100% MT, with train duration of 2 seconds and intertrain interval of 1 minute, yielding 1600 pulses per session. These stimulation parameters are in accordance with international TMS safety guidelines. 31, 32 Total pulses were 24,000 pulses for the once per day rTMS group and 48,000 for the twice per day rTMS group. For active TMS, the coil was placed flat against the scalp with the handle and short axis of the coil oriented in a parasagittal plane and the intersection of the figure-8 windings centered over PFC. Sham TMS was delivered in the same anatomical location with identical stimulation parameters but with the lateral edge of the coil rotated 90 degrees away from the scalp. The sham subjects went through the same procedures as the active TMS subjects up to the point of the coil rotation.
Outcome Measures
Outcome measures were the 17-item Hamilton Depression Rating Scale score (HDRS) (Hamilton, 1960) 33 and the Clinician Global Impressions-Severity of Illness score (CGI-S). 34 Patients were evaluated at baseline (before randomization) and at the end of the first, second, third, and fifth week. Additional baseline data obtained by patient interview and case note review included age, sex, history of depression and ECT, number of medication treatment steps for the current depressive episode (according to the criteria of Thase and Rush 29 ), and current antidepressant and/or benzodiazepine medication.
For HDRS, response was defined as a decrease of 50% or more from baseline and remission as HDRS score of less than 8. For the CGI-S, response was defined as an endpoint rating of 3 or less (corresponding to "mildly ill" or better) whereas remission as an endpoint rating of 2 "borderline mentally ill" or 1 "normal/ not at all ill". 34 The interrater reliability (intraclass correlation coefficient) for the outcome measures were 0.95 for HDRS and 0.97 for the CGI-S.
Statistical Analysis
Continuous variables are presented as mean and standard deviation (SD), whereas qualitative variables are presented as absolute and relative frequencies. Bonferroni post hoc correction for multiple comparisons was used to assess differences in baseline characteristics between groups.
Mixed-effects regression was used to study the differences in the outcome variables over the 3-week treatment period and the follow-up period and evaluate differences among the 4 study groups. For each outcome measure, a mixed-effects model was used to evaluate the treatment effect during the 5-week course, allowing for different intercept and slope for each individual (the random intercept and slope model constituted an improvement over the simpler random intercept model as indicated by the corresponding likelihood ratio tests for nested models: HDRS, χ 2 Â 2 = 32.5, P < 0.001; CGI-S, χ 2 Â 2 = 29.3, P < 0.0001). The reference category for the group was set as the A1 group and the follow-up (week 5) to facilitate the interpretation of the coefficients in Table 2 . The analysis was repeated considering the 5-point time variable as numerical. This approach allows us to consider a quadratic effect for time. One-way analysis of variance was used to evaluate group differences at the follow-up.
Multiple logistic regression analyses using a stepwise method including various independent variables (ie, sex, age, stage of treatment resistance according to the Thase and Rush criteria, current antidepressant and benzodiazepine use, and HDRS baseline score) were performed to identify predictors of treatment outcome (response or remission) based on HDRS and CGI-S scores. All reported P values are 2-tailed, and statistical significance was set at 0.05. Analyses were conducted using STATA 13 (StataCorp LP, TX).
Power Analysis
Power analysis methodology for this study represents a design with 4 levels of the between-subject factor (4 treatment groups) and 5 levels of the within-subject factor (time in weeks). Sample size was determined using previously published effect size estimates (Avery et al 35 : differences in rates of response between the sham and TMS groups with a 0.69 effect size) and indicated 90% power for a 2-tailed test of significance at P < 0.05.
RESULTS
Sample Characteristics per Study Group
One hundred seventy-seven patients were screened, of whom 105 met eligibility criteria and 98 consented and were randomized (Table 1) . The 4 study groups were similar in terms of age, sex, medication, Rush and Thase stage, and HDRS and CGI scores at baseline (Table 3 ). Of the 98 randomized patients, 27 patients received once-daily sessions of active HF-rTMS (A1 group), 27 patients received twice-daily sessions of active HF-rTMS (A2 group), 20 patients received sham stimulation once a day (S1 group), and 24 received twice a day sham stimulation (S2 group). Eighty-nine subjects completed the 5-week trial and 9 (9%) discontinued (2 from A1 group, 2 from A2 group, 2 from S1 group, and 3 from S2 group) (Table 1 ): 1 for protocol violation (a treater discussed study protocol with a patient), 2 because of exacerbation of preexisting headache, 5 were unable to attend treatment sessions because of financial and work-related reasons, and 1 was hospitalized with influenza. The basic analysis was conducted on the intent-to-treat sample, that is, the 96 individuals who had measurements at week 1 ( Table 1 ). The sample was reduced to 89 for models that refer to the differences between baseline and follow-up (for details see the "Results" section).
Treatment Efficacy
Time Course Analysis of Change of Mean Scores for HDRS and CGI-S
There were no significant differences among treatment groups on any baseline measure (Table 3) . Table 4 and Figure 1 present the changes in outcome measures over time for each group separately. The mean scores were significantly different between the A1 group and the other 3 groups (week 5, follow-up) for both outcome measures. In particular, the A2 group had significantly lower mean scores than the A1 group, whereas both sham groups had significantly higher scores. No significant interactions emerged for the A2 group and time, whereas for the sham groups, the interactions were significant with the exception of the fourth week for CGI-S. In relation to the score differences between the primary end point (3 weeks) and the end of the study (5 weeks), no statistically significant differences were present in the HDRS in the S1 (P = 0.75) and S2 (P = 0.118), whereas the differences were significant in the A1 (P = 0.001) and A2 (P < 0.001) groups. In the case of CGI, the only significant difference was present in the A2 group (P = 0.046, whereas P > 0.1 in all other groups).
The analysis considering time as a numerical variable yielded similar results. Significant effects emerged for the linear (HDRS: b t = 1.2, P < 0.001/CGI-S: b t = 0.3, P < 0.001) and the quadratic time (HDRS: b t2 = 0.5, P < 0.001/CGI-S: b t2 = 0.06, P < 0.001). The A1 group had significantly higher mean than the A2 group (HDRS: b A2 = −3.6, P = 0.026/CGI-S: b A2 = −0.7, P = 0.011) and lower mean than the sham groups (HDRS: b S1 = 15.3, P = 0.026, b S2 = 17.2, P < 0.001/CGI-S: b S1 = 2.3, P < 0.001, b S2 = 2.6, P < 0.001). No significant interactions with time emerged for the A2 group, but the interactions were again significant for the sham groups (P < 0.001 in all cases).
Response and Remission
Only 1 individual (2.5%) in the sham groups had a treatment response based on the HDRS score as opposed to 29 (59.2%) for the active groups (χ 2 = 31.666, df = 1, P < 0.001). Similarly, only 5 individuals (12.5%) have a response based on CGI-S scores in the sham groups as opposed to 49 (100%) in the active groups (χ 2 = 70.664, df = 1, P < 0.001). The logistic regression found that likelihood of a treatment response (in terms of HDRS) in the active rTMS groups was significantly associated only with frequency of rTMS sessions (odd ratio [OR] = 5.2, P = 0.027), baseline HDRS score (OR = 0.7, P = 0.010), and current medication status (OR = 5.2, P = 0.033) (with each OR controlled for the other two). Logistic regression could not be done for CGI-S scores because all individuals had a CGI-S score of 3 or less.
No one in the sham groups was in remission (based on HDRS) at follow-up, as opposed to 12 (24.5%) of the individuals who received active treatment (χ 2 = 11.323, df = 1, P = 0.001). Similar results occurred for remission based on CGI-S (2.5% vs 51% for the sham and active groups, respectively; χ 2 = 25.072, df = 1, P < 0.001). The logistic regression found that likelihood 
Integrity of the Blind
The 4 treatment groups did not differ significantly in their guesses about which treatment they received after the first (P = 0.8) and last rTMS session (P = 0.6). Likewise, raters did not guess better than chance which subjects received active treatment (P = 0.7). However, the response to rTMS treatment did seem to influence subjects' thoughts about what they received. After the 15th day of rTMS, 100% of the 12 patients (3 from the A1 group and 9 from the A2 group) who achieved remission thought they were receiving active TMS versus 46.8% of nonremitters (36/77) (P = 0.001). Similarly, after the 15th day of rTMS, 82.7% of the patients (24/29) with a treatment response thought they were receiving active TMS versus 40% (24/60) of nonresponders (P < 0.001).
Adverse Effects
The rTMS sessions were generally well tolerated. No seizures occurred. Seven patients from the A1 group, 6 from the A2 group, 5 from the S1 group, and 6 from the S2 group complained of discomfort at the site of stimulation. Nine subjects (3 from A1 group, 2 from A2 group, 1 from S1 group, and 3 from S2 group) experienced exacerbation of preexisting headache; 1 subject from A1 group and 1 from S2 group discontinued the trial because of this. One patient was hospitalized with influenza (not considered study related). There were no significant group differences in proportion of subjects with various adverse effects.
DISCUSSION Findings
To our knowledge, this is the first randomized shamcontrolled trial to compare the effectiveness of twice-daily versus once-daily HF-rTMS sessions for treatment of TRD. It is proposed that twice-daily sessions might be more effective in terms of both response and remission rates. There was a slight discrepancy, however, between the CGI-S results and HDRS results (increased odds of remission were present for CGI-S by stimulating twice rather than once per day, whereas there was a marginal result for HDRS); yet, other studies have also come across similarly discrepant results when different outcome measures were used. 25 It is of note, that Bandelow et al 34 suggest that a CGI-S score of 2 or less indicates remission, whereas a CGI-S score of 1 indicates complete or symptom-free remission (this might explain the discrepancy observed between the CGI-S remission scores and HDRS-remission scores).
Relation to Previous Studies
Number of Stimulations per Session and per Day and Duration of Treatment per Week
In our study, a 3-week treatment period was used; each session consisted of 1600 pulses (24,000 pulses for the A1 group and 48,000 for the A2 group for the whole course). Avery et al, 35 in a 3-week controlled study comparing active and sham stimulation (1600 pulses per day and 24,000 pulses for the whole course similar to the A1 group in this study), found response rate to be 31% (compared with 37% for the A1 group in this study) and remission rate to be 20% (compared with 11% for the A1 group in this study) based on HDRS scores. Nevertheless, results may be different from other RCT studies 10 ; various factors could have contributed to this: age of patients, chronicity of the condition, medication, localization of the stimulation point, and the frequency of TMS stimulation might have also been a factor. We have rarely noticed so good results with a frequency of 10 Hz compared with 20 Hz. 36 In the study by O'Reardon et al, 10 stimulation period was extended from 4 to 6 weeks. Indeed, larger stimulation periods might investigate better the efficacy of rTMS; however, withdrawal rate could be high. 37 In the study, we have chosen a 3-week stimulation period to retain the larger number of patients possible; this was actually the minimum treatment period suggested in the study by George et al. Having more rTMS sessions during each day [38] [39] [40] [41] and increased number of pulses per day, [42] [43] [44] [45] as in our study, might retain more patients 37 and have faster antidepressant effects. Within this context, Holtzheimer et al 42 used 15,000 rTMS pulses for over 2 days, whereas Hadley et al 43 used 6800 pulses per session and 5 sessions per week (34,000 pulses per week) for 2 weeks (10 sessions). MacDonald et al 44 found that ppatients who remitted during fast left-sided treatment received a mean of 26 active treatments (90,000 pulses). Finally, George et al 45 delivered 54,000 pulses of left prefrontal rTMS over 3 days to suicidal inpatients and found high doses of rTMS to be feasible and safe over a short treatment period. We think that the number of pulses per day is a very significant factor for remission; however, many patients, especially the ones experiencing adverse effects, may need more sessions per day because they cannot tolerate increased number of pulses per session.
Adverse Effects
The treatment was relatively well tolerated with no significant difference in adverse effects between rTMS and sham groups or between once-daily and twice-daily sessions, and high retention rate (90.8%) HF-rTMS has previously been found safe even in patients with serious physical conditions. 46 
Factors Influencing Response and Remission
Both twice-daily rTMS sessions and concurrent antidepressant medication were associated with better treatment response. Recently, it has been proposed 11, 47 that greater rates of response and remission would be seen if TMS were delivered in combination with pharmacotherapy. Several studies [48] [49] [50] and metaanalyses 51, 52 suggest that HF-rTMS may accelerate response to antidepressants and provide clinical improvement comparable with triidothyronine and pindolol augmentation. In the present study, we found that patients on antidepressants exhibited greater response but not greater remission rates, possibly because of short follow-up period.
In previous studies, younger age, 12,53,54 less treatment resistance, 53, 55, 56 lower baseline symptom severity, 12, 54 and lack of comorbid anxiety disorders 56 were associated with better response. In our study, no effect was found regarding age possibly because all our patients were relatively young; we did find the expected association with lower baseline symptom severity but not with TRD stage. 29 We did not examine the presence of comorbid anxiety disorders. Carpenter et al 12 found that TRD level was a modest predictor of benefit from TMS treatment, whereas Shutter 8 also reported that treatment resistance does not play a major role in TMS antidepressant effect. Finally, Demitrack and Thase 57 found rTMS efficacy to be similar to that of antidepressant therapy or atypical antipsychotic augmentation in TRD.
Blinding and Placebo Effects
Treaters were not blind to treatment allocation, potentially jeopardizing the blinding of subjects. Furthermore, we did not have a sham coil that could deliver somatosensory sensations matched to active stimulation. 11 Sham TMS consisted of active pulses delivered to the same anatomical location with identical stimulation parameters but with the lateral edge of the coil rotated 90 degrees away from the scalp. This sham rTMS approach produced acceptable levels of blinding in previous studies. 58 Furthermore, debriefing data from both the patients and raters indicated that the blind was successfully maintained. George et al 11 reported that 48% of clinical raters guessed correctly (35% correct for active rTMS and 59% for sham), whereas 84% of their guesses were not confident. Lisanby et al 59 found that tilting the coil at a 90-degree angle, like in the present study, produced minor therapeutic effects (only 29% of the peak integrated voltage of the actual TMS stimulation). In our study, sham rTMS seemed to have no therapeutic effect because only 1 subject in the sham groups had any treatment response. In other studies, larger response and remission rates were observed for the sham stimulation group. 11, 35 George et al 11 reported that those patients who remitted either in the sham or the active group seemed to be less resistant to treatment. It is possible that our patients were more resistant to treatment than the ones in other studies. 11, 35 For example, in the study by Avery et al 35 very similar to ours (for what concerns stimulation parameters and sham condition), the TMS group and sham group differed by 25% [31% (11/35) −6% (2/33)] in response rate and by 17% [20% (7/35)−3% (1/33)] in remission rate. In our study, A1 group and S1 group differed in response rate by 32% [37% (10/27)−5% (1/20)], whereas remission in the 2 groups differed by 11% [11% (3/27) −0% (0/20)]. It is worth noting that there was a greater remission rate in the study by Avery et al 35 both for the active and sham groups. In our study, only 3 of 27 subjects (11%) from A1 group remitted compared with 7 of 35 (20%) in the active group and 1 of 33 (3%) in the sham group in the study by Avery et al. 35 
Localization of PFC
Precise PFC location could increase TMS efficacy. 11, 60 We used structural magnetic resonance imaging to locate PFC; in 34.7% of patients, PFC was found in a more anterior position than the one dictated by the 5-cm rule.
Study Limitations
A number of study limitations should be taken into account. First, raters and treaters, although blind to the study protocol, were from the same academic center. Second, we were not able to evaluate cognitive function; however, several studies have indicated that rTMS is relatively safe in this domain. 25, 61 Third, the follow-up period was short because we did not want TRD patients to remain untreated for longer periods. This study cannot comment on the duration of effects beyond 2 weeks.
CONCLUSIONS
Twice per day active HF-rTMS might be more effective than once per day active HF-rTMS in patients with TRD. Larger multicentered studies should verify the aforementioned results.
